Overview
Rezo Therapeutics maps disease networks to develop precision medicines using its SSD platform, which integrates proteomics, genetics, structural biology, chemistry, and bioinformatics to build networks of molecular interactions in diseases. The platform analyzes protein‑protein and genetic interactions to identify druggable targets that traditional target‑driven methods might miss, with an initial focus on solid tumor oncology and partnerships for other areas. It differentiates itself by combining high‑level biology with computational network biology in one platform to map whole disease networks rather than chasing single targets, supported by leadership rooted in UCSF’s QBI. The company aims to translate network discoveries into targeted therapies and grow its pipeline through collaborations and strategic partnerships.
Work here?Claim your company
Simplify's take
What believers are saying
- Google-backed modeling work in January 2026 suggests stronger computational infrastructure.
- Cristiana Guiducci's CSO appointment adds oncology discovery credibility from Nurix and immunology.
- Forty employees and continued leadership changes indicate ongoing program investment through 2026.
What critics are saying
- Rezo still has no disclosed clinical candidates or human data as of August 2026.
- Zero active job postings in 2026 signal slowed hiring and possible capital conservation.
- If SSD never yields a clinical asset, Rezo becomes a platform story without product traction.
What makes Rezo Therapeutics unique
- Rezo's SSD platform combines proteomics, genetics, chemistry, and bioinformatics for network mapping.
- UCSF founders Nevan Krogan and Kevan Shokat anchor unusually deep academic disease-biology expertise.
- Derek Hicks joined as CEO in August 2025, adding Pfizer, Spark, and Intellia experience.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards